CORDIS - EU research results

A breakthrough respiratory monitoring device incorporating novel nanotechnology-based sensors

Project description

Innovative respiratory disease monitoring

Chronic obstructive pulmonary disease (COPD) is an inflammatory disease of the lungs that represents a rising threat, with estimates pointing to it becoming one of the main causes of death by 2030. COPD, as other chronic respiratory conditions, requires accurate disease monitoring. However, despite its importance, accurate monitoring is lacking, resulting in inadequate treatment and high costs to healthcare systems. The EU-funded SenseGuard project proposes a reliable solution generated from a pioneering nanosensor-based technology that is unique for respiratory disease monitoring. The solution consists of an advanced wireless, wearable tool that allows continuous and non-invasive monitoring of lung functions based on patients’ normal breathing. The project aims to finalise the solution and confirm it in clinical studies.


Disease monitoring is key for patients with chronic respiratory conditions. Chronic Obstructive Pulmonary Diseases (COPD) is a long-term condition that causes inflammation in the lungs, making breathing difficult. It is a large growing public health problem, expected to become one of the leading causes of death by 2030. Nevertheless, COPD patients lack of a constant and accurate monitoring throughout their disease. This can result in non-adequate therapeutic measures, which can often lead to potential serious effects on patient’s status and high costs for healthcare systems.

SenseGuard is a reliable solution for monitoring of patients with respiratory diseases, including COPD, based on a unique nanosensor-based technology. It is an innovative wireless wearable device that enables continuous and non-invasive monitoring of lung functions derived from patients' tidal (normal) breathing.

NanoVation is an Israeli SME, founded in 2014, which develops and integrates nanomaterial-based sensors for medical applications and general purposes and is run by an experienced and multi-disciplinary team of 12 people.
During the proposed Phase 2 project, NanoVation will finalise the development of the SenseGuard device and validate its efficacy and safety in dedicated clinical studies.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 2 497 029,50
Ha'Oren 68a/4
3009500 Ramay Ishai

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 3 567 185,00